Healthcare Names Gain Today: Argent Biopharma, Vectus Biosystems and Alcidion in Focus

Sonal Goyal

13 November 2026 02:46 PM AEDT

Healthcare Names Gain Today: Argent Biopharma, Vectus Biosystems and Alcidion in Focus

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Argent Biopharma (ASX:RGT), Vectus Biosystems (ASX:VBS) and Alcidion Group (ASX:ALC) all traded higher during the 13 November 2026 session.
Alcidion shares rose 14.29%, Argent Biopharma 10.53% and Vectus Biosystems 10.00%.
Between them, the companies reported an FDA meeting, a new licence and expanded hospital contracts.

During the Trading session on 13 November 2026, Argent Biopharma Ltd (ASX:RGT) shares were trading at $0.021, up 10.53%, Vectus Biosystems Ltd (ASX:VBS) shares were at $0.055, up 10.00%, and Alcidion Group Ltd (ASX:ALC) shares were at $0.12, up 14.29%. The S&P/ASX 200 was down 0.73% at 9,079.70 at 12:39 pm AEDT over the same session. Two of the companies are drug developers and the third supplies software to hospitals.

Argent Biopharma (ASX:RGT)

Argent Biopharma has refined its strategy to focus on immune modulation and inflammatory disease following the global licensing of CannEpil. Its September 2026 quarterly report, released on 23 October 2026, said the company signed an exclusive, royalty-bearing licence to commercialise the antiviral applications of NLC's Tollovir, Tollovid and NutraVir products. The lead internally developed program is RGT-CA91980, and the company said it does not present CimetrA as an anti-ageing medicine.

Vectus Biosystems (ASX:VBS)

Vectus Biosystems is developing VB0004, an oral compound for idiopathic pulmonary fibrosis. Its quarterly report, released on 29 October 2026, said the US Food and Drug Administration granted its request for a pre-IND Type B meeting on the program. Written FDA responses are expected by mid-November 2026, and Cardinal Health Regulatory Services has been appointed as its US regulatory agent. The company has completed a Phase Ia study in healthy volunteers.

Alcidion Group (ASX:ALC)

Alcidion is a Melbourne-based healthcare technology company. Its trading update dated 29 October 2026 said it expanded its contract with Northern Care Alliance NHS Foundation Trust, with a total contract value of $7.5 million over three years, and extended its Health NZ contract in MidCentral to include Whanganui Hospital. FY27 contracted Revenue stood at $50.0 million at 30 September 2026, up 38%, and FY27 guidance was reconfirmed.

Final Word

Each company has reported progress in its latest update, whether a regulatory milestone, a licence or contract growth. The next updates will show how these steps progress.

FAQs

Q: What regulatory step did Vectus Biosystems announce?

A: The FDA granted its request for a pre-IND Type B meeting on VB0004, with written responses expected by mid-November 2026.

Q: How much is the expanded NCA contract worth?

A: The total contract value is $7.5 million over three years, with options to extend up to five years.

Q: What licence did Argent Biopharma sign?

A: It signed an exclusive, royalty-bearing licence to commercialise the antiviral applications of NLC's Tollovir, Tollovid and NutraVir products.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.